|By PR Newswire||
|March 13, 2014 06:30 AM EDT||
CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014.
"In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our randomized clinical program continues to move ahead with six sponsored studies currently enrolling patients in a range of indications. Each of these studies will advance in parallel with our ongoing head and neck program which we are currently in the process of designing a follow-on registration study for discussion with regulators."
Since January 1, 2013, specific highlights announced by the Company include:
Clinical Trial Results
- Top-line data for the endpoints in a double blinded, randomized clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). An analysis was performed on an intent-to-treat basis of 118 patients with loco-regional head and neck cancer, with or without metastases. Patients in the control arm were treated with carboplatin and paclitaxel, while patients in the test arm were treated with carboplatin, paclitaxel and REOLYSIN. The analysis showed a median progression free survival (PFS) of 94 days (13.4 weeks) in the test arm (n=62), versus 50 days (7.1 weeks) in the control arm (n=56). The test arm maintained a PFS benefit over the control arm through five cycles of therapy. An analysis of 88 loco-regional patients that did not receive additional therapy following discontinuation of study treatment showed a median overall survival (OS) of 150 days (21.4 weeks) in the test arm (n=50), versus 115 days (16.4 weeks) in the control arm (n=38). REOLYSIN was deemed safe and well-tolerated by patients. The side effects experienced by patients in the test arm of the study were consistent with expectations based on outcomes of earlier clinical studies using REOLYSIN. Patients on the test arm of the study experienced a higher incidence of flu-like symptoms consistent with treatment with a virus, most commonly mild fever, chills, nausea and diarrhea, on both a per-patient and a per-cycle basis. Fewer patients required dose reductions of paclitaxel due to neuropathy or neurotoxicity on the test arm than the control arm (zero in the test arm versus six in the control arm; p=0.028). On this basis, the Company intends to explore the potential chemoprotective and neuroprotective properties of REOLYSIN in future clinical studies;
- Positive final results from a U.S. Phase 2 study examining the use of REOLYSIN in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016). Response evaluation for 36 evaluable patients showed 11 partial responses (PR) (30%) (EGFR amplified, five; BRAF two; Kras, three; EGFR mutated, one), 21 stable disease (SD), and four progressive disease (PD). The data also correlated a number of molecular abnormalities with best response, PFS and one-year survival. Current data in these patients demonstrates that 20 of 36 evaluable patients (56%) survived a year or more. There were 13 patients with only EGFR mutations or amplifications, of whom nine (69.2%) survived a year or longer. Four of four (100%) patients with BRAF and EGFR amplification survived a year or longer;
- Final tumor response and PFS data from a U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). Of the 25 evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumor shrinkage. When evaluated for best response, which is the best percentage response recorded on study compared to baseline, 10 patients (40%) had PR, while a further 14 (56%) showed SD, and one (4%), had PD. Using RECIST criteria to evaluate best overall response, 10 patients (40%) had PRs, 12 (48%) showed SD and three (12%), had PD. 31.8% of patients with sufficient follow up had a PFS greater than six months;
- Reaching the stage 1 endpoint in a U.S. Phase 2 clinical trial in patients with metastatic melanoma (REO 020) after only 14 patients were enrolled. The primary objective of this Phase 2 trial was to assess the antitumor effect of the treatment regimen in the study population in terms of objective response rates. The secondary objectives were to assess progression-free survival and overall survival for the treatment regimen; the disease control rate (complete response (CR) plus PR plus SD) and duration, and to assess the safety and tolerability of the treatment regimen in the study population. Three of the 14 patients exhibited a PR, and an additional seven patients had SD for a disease control rate of 71.5%; and
Positive preliminary results from a Phase 1 study examining the
intravenous administration of REOLYSIN in combination with FOLFIRI in
patients with metastatic colorectal cancer (REO 022) in a poster
presentation at the ASCO Gastrointestinal Cancers Symposium. Of the 18
patients evaluable for response there was one PR and nine had SD. The
combined overall PFS of FOLFIRI-naïve and FOLFIRI-failed patients was
7.4 months. The authors concluded that the combination of REOLYSIN and
FOLFIRI was safe and well tolerated and resulted in disease control in
the majority of evaluable patients, including patients that had
previously progressed on Irinotecan.
- At December 31, 2013 the Company reported $27.2 million in cash, cash equivalents and short-term investments; and
- Subsequent to year end, entry into a share purchase agreement with Lincoln Park Capital Fund, LLC that will provide an initial investment in Oncolytics of US$1.0 million and make available additional periodic investments of up to US$25.0 million over a 30-month term.
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF FINANCIAL POSITION|
|Cash and cash equivalents||25,220,328||19,323,541|
|Total current assets||27,689,568||21,668,842|
|Property and equipment||532,459||409,248|
|Total non-current assets||532,459||409,248|
|Liabilities And Shareholders' Equity|
|Accounts payable and accrued liabilities||6,008,661||7,291,310|
|Total current liabilities||6,008,661||7,291,310|
|Issued: December 31, 2013 - 84,803,818|
|December 31, 2012 - 76,710,285||228,612,564||198,155,091|
|Accumulated other comprehensive loss||79,698||(57,115)|
|Total shareholders' equity||22,213,366||14,786,780|
|Total liabilities and equity||28,222,027||22,078,090|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS|
|For the years ending December 31,||
|Research and development||18,506,064||31,402,625||23,386,685|
|Loss before the following||(23,898,724)||(36,688,050)||(28,721,267)|
|Write down of asset available for sale||—||—||(735,681)|
|Change in fair value of warrant liability||—||—||36,000|
|Loss before income taxes||(23,527,239)||(36,343,047)||(29,004,701)|
|Income tax expense||(5,408)||(30,474)||(40,000)|
Other comprehensive income items that may
be reclassified to net loss
|Net comprehensive loss||(23,395,834)||(36,313,135)||(29,005,542)|
|Basic and diluted loss per common share||(0.28)||(0.48)||(0.41)|
|Weighted average number of shares (basic and diluted)||83,530,981||76,102,062||70,911,526|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY|
|As at December 31, 2010||155,439,610||4,108,652||19,399,489||(156,660)||(142,396,131)||36,394,960|
|Net loss and comprehensive income||—||—||—||39,159||(29,044,701)||(29,005,542)|
|Exercise of warrants||21,487,080||(1,455,025)||—||—||—||20,032,055|
|Exercise of stock options||355,876||—||(62,473)||—||—||293,403|
|Share based compensation||—||—||1,805,503||—||—||1,805,503|
|As at December 31, 2011||177,282,566||2,653,627||21,142,519||(117,501)||(171,440,832)||29,520,379|
|Net loss and comprehensive income||—||—||—||60,386||(36,373,521)||(36,313,135)|
|Issued, pursuant to a bought deal financing||19,386,903||376,892||—||—||—||19,763,795|
|Expiry of warrants||—||(2,653,627)||2,653,627||—||—||—|
|Exercise of stock options||1,485,622||—||(400,632)||—||—||1,084,990|
|Share based compensation||—||—||730,751||—||—||730,751|
|As at December 31, 2012||198,155,091||376,892||24,126,265||(57,115)||(207,814,353)||14,786,780|
|Net loss and comprehensive income||—||—||—||136,813||(23,532,647)||(23,395,834)|
|Issued, pursuant to a bought deal financing||30,218,796||—||—||—||—||30,218,796|
|Expiry of warrants||—||—||—||—||—||—|
|Exercise of stock options||238,677||—||(59,437)||—||—||179,240|
|Share based compensation||—||—||424,384||—||—||424,384|
|As at December 31, 2013||228,612,564||376,892||24,491,212||79,698||(231,347,000)||22,213,366|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|For the years ending December 31,||
|Net loss for the year||(23,532,647)||(36,373,521)||(29,044,701)|
|Amortization - property and equipment||131,623||109,275||92,590|
|Share based compensation||424,384||730,751||1,805,503|
|Change in fair value of warrant liability||—||—||(36,000)|
|Write down of asset available for sale||—||—||735,681|
|Unrealized foreign exchange loss||(89,721)||89,890||115,234|
|Net change in non-cash working capital||(1,374,172)||1,187,967||3,790,510|
|Cash used in operating activities||(24,440,533)||(34,255,638)||(22,541,183)|
|Acquisition of property and equipment||(254,834)||(126,412)||(257,790)|
|Redemption (purchase) of short-term investments||(32,416)||(32,441)||1,672,459|
|Cash provided by (used in) investing activities||(287,250)||(158,853)||1,414,669|
|Proceeds from exercise of stock options and warrants||179,240||1,084,990||14,824,658|
|Proceeds from public offering||30,218,796||19,763,795||—|
|Cash provided by financing activities||30,398,036||20,848,785||14,824,658|
|Increase (decrease) in cash||5,670,253||(13,565,706)||(6,301,856)|
|Cash and cash equivalents, beginning of year||19,323,541||32,918,751||39,296,682|
|Impact of foreign exchange on cash and cash equivalents||226,534||(29,504)||(76,075)|
|Cash and cash equivalents, end of year||25,220,328||19,323,541||32,918,751|
To view the Company's Fiscal 2013 Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's annual filings which will be available on www.sedar.com and on www.oncolyticsbiotech.com/for-investors/financials.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2014 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Mar. 30, 2017 12:00 PM EDT Reads: 2,694
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
Mar. 30, 2017 11:15 AM EDT Reads: 3,581
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...
Mar. 30, 2017 10:45 AM EDT Reads: 1,097
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
Mar. 30, 2017 10:45 AM EDT Reads: 2,957
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Mar. 30, 2017 10:30 AM EDT Reads: 527
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Mar. 30, 2017 10:30 AM EDT Reads: 1,890
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
Mar. 30, 2017 10:15 AM EDT Reads: 2,458
SYS-CON Events announced today that SD Times | BZ Media has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. BZ Media LLC is a high-tech media company that produces technical conferences and expositions, and publishes a magazine, newsletters and websites in the software development, SharePoint, mobile development and commercial UAV markets.
Mar. 30, 2017 10:00 AM EDT Reads: 4,571
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Mar. 30, 2017 09:15 AM EDT Reads: 1,786
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to max...
Mar. 30, 2017 09:15 AM EDT Reads: 851
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Mar. 30, 2017 08:00 AM EDT Reads: 4,605
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Mar. 30, 2017 06:00 AM EDT Reads: 3,194
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
Mar. 30, 2017 05:00 AM EDT Reads: 10,128
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Mar. 30, 2017 04:45 AM EDT Reads: 3,370
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Mar. 30, 2017 04:45 AM EDT Reads: 3,414